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ABSTRACT
Background: Pain on injection of propofol is a common adverse event.
Objective: The aim of this study was to investigate the effect of a combination 
of ketorolac pretreatment and premixed lidocaine in propofol compared with placebo 
on propofol injection pain.
Methods: In this prospective, randomized, double-blind, placebo-controlled 
study, Korean patients scheduled for elective plastic surgery were randomized to 1 of 
3 groups. Group A received 15 mg ketorolac in saline IV as pretreatment. Groups B
and C received 3 mL saline IV as pretreatment. Sixty seconds after pretreatment, 
groups A and B received a mixture of lidocaine 1% in propofol 1% at a 1:10 ratio and 
group C received propofol 1% alone. Pain during propofol injection was assessed on a
4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe).
Results: Ninety patients (41 men, 49 women; mean age, 41.7 years; mean 
weight, 63 kg) completed the study. The overall incidence of pain on propofol injec-
tion was significantly lower in groups A (16.7%) and B (36.7%) than in group C 
(83.3%; both, P < 0.001). There was no significant difference in the incidence of pain 
between groups A and B. However, the patients in group A reported a significantly 
lower incidence of moderate (0% vs 33.3%; P < 0.001) and severe pain (0% vs 20%; 
P = 0.024) compared with those in group C. There were no significant differences in
the incidences of moderate and severe pain between the B and C groups.
Conclusions: In this Korean population, premixed lidocaine in propofol with 
or without ketorolac pretreatment was associated with significantly less pain when
compared with placebo. The combination of ketorolac pretreatment and premixed
lidocaine in propofol was more effective in decreasing the incidence of moderate or 
severe pain compared with placebo. (Curr Ther Res Clin Exp. 2009;70:351–358) © 
2009 Excerpta Medica Inc.




Propofol is a popular anesthetic induction drug that can cause considerable discomfort
or pain on injection.1–3 During induction of anesthesia, ~37.5% to ~90.0% of pa-
tients experience pain on propofol injection when a vein on the dorsum of the hand is 
used. Many methods have been proposed to reduce the incidence of pain on propofol
injection, including varying injection speed and carrier fluid, adjusting dilution tem-
perature, and adding other concomitant drugs.4–8
Peripheral veins are innervated with polymodal nociceptors that mediate the 
responses to an injection that cause pain.9 Pain on injection of propofol can be im-
mediate or delayed. Immediate pain may result from a direct irritant effect, whereas
delayed pain may be caused by an indirect effect via kinin cascade.10,11 A high con-
centration of free propofol in the aqueous phase of an emulsion activates the kallikrein-
kinin system in plasma, liberating bradykinin. Bradykinin acts on the local vein to 
dilate it and make it permeable. In this bradykinin-modified vein, the aqueous phase 
of propofol may contact more free nerve endings outside the endothelial layer of the
vessel, causing pain.12
Although the exact cause of propofol injection pain remains unknown, the direct
irritant effect of propofol and the activation of the plasma kallikrein-kinin cascade 
have been suggested.13,14 Some research has theorized that pain on propofol injection
may be reduced by administration of an NSAID and venous occlusion of the forearm 
with a tourniquet for 2 minutes before injection.13,14 It was theorized that venous oc-
clusion was necessary to keep the NSAID in the vein long enough to produce the
postulated localized antiprostaglandin effect and reduce the release of kininogens.13,14
However, although the venous occlusion technique allows time for the NSAID to
mediate its analgesic effect at the peripheral site, increasing the tourniquet time may 
result in greater discomfort to the patient.15
One well-accepted technique is the use of a premixture of lidocaine in propofol.7,8,16
Mixing lidocaine with propofol has been reported to reduce injection pain.7,8,16 Lido-
caine may act by local anesthetic effect on the vein and by stabilizing the kinin cas-
cade.7 However, the incidence of pain has been reported to be between 25.7% and
48.9% despite the addition of lidocaine.7,8,16,17
Yamakage et al6 reported that premixing lidocaine in propofol did not decrease free 
propofol concentration, suggesting that lidocaine acts mainly through inhibition of pain 
transmission. King et al16 observed that 20 mg of lidocaine premixed in 200 mg propofol
significantly reduced the incidence of injection pain from 73% to 32%. Tan and Hwang8
reported that the incidence of propofol injection pain was reduced to 25.7% in their study 
population using a mixture of lidocaine 1% and propofol 1% at a 1:10 ratio. 
A few studies have investigated the effect of ketorolac in preventing pain on propo-
fol injection. Ketorolac, a potent cyclooxygenase inhibitor that blocks prostaglandin
production, is widely used for postoperative analgesia.18 Yull et al14 reported that the 
incidence of severe pain due to propofol injection was reduced by administration of 
10 mg ketorolac with venous occlusion for 2 minutes. The same dose of ketorolac
without venous occlusion did not decrease the incidence of pain. Huang et al19 ob-
served that pretreatment with either 15 or 30 mg ketorolac without venous occlusion
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achieved the same pain relief effect of ketorolac 10 mg IV with venous occlusion. 
However, injection pain still occurred at a rate of 23.3%.
Recently, combination treatment with partially effective drugs has been suggested 
for the prevention of injection pain.15,17,20 No studies were identified that assessed the 
efficacy of the combination of ketorolac pretreatment and premixture of lidocaine in
propofol on preventing pain on injection. Therefore, this study was designed to inves-
tigate the analgesic effect of the combination of ketorolac pretreatment without a
tourniquet and premixed lidocaine in propofol, compared with premixed lidocaine in
propofol alone (positive control group) and placebo (negative control group) during 
propofol injection.
PATIENTS AND METHODS
This prospective, randomized, double-blind, placebo-controlled study was approved 
by the Institutional Review Board of Kyungpook National University Hospital,
Daegu, Republic of Korea, and was conducted between December 2008 and January 
2009. Eligible patients were scheduled for elective plastic surgery under general an-
esthesia and met American Society of Anesthesiologists Physical Status Classifica-
tion I (no organic, physiologic, biochemical, or psychiatric disturbance) or II (mild
to moderate systemic disturbance that may or may not be related to the reason for
surgery). Written informed consent was obtained. Patients who had sensitivity to 
NSAIDs or propofol; were currently taking NSAIDs; or had asthma, a coagulation
disorder, or renal or cardiac problems were excluded. The study was limited to adult 
patients aged 18 to 75 years.
After arrival in the operating room, a 20 G intravenous catheter was inserted on 
the dorsum of the nondominant hand and a 3-way tap was directly connected to the
catheter. Administration of Ringer’s lactate 5 mL/kg/h was started after injection of 
study drugs or test substances. Patient monitoring consisted of pulse oximetry, ECG, 
and noninvasive blood pressure.
Patients were randomized to 1 of 3 groups using a sealed-envelope technique in the 
preoperative holding area. Ninety sealed envelopes, each containing the name of 1 of 
the 3 treatment groups, were prepared before the initiation of the study. An anesthe-
siologist who was not involved in this study selected an envelope for each patient. 
Patients in group A received 15 mg ketorolac plus 2.5 mL 0.9% saline IV (total vol-
ume 3 mL) as pretreatment, based on dosing used in a previous study.19 Patients
randomized to groups B and C received 3 mL 0.9% saline IV as pretreatment. All 
pretreatment substances were injected over 15 seconds and were administered 60 sec-
onds before propofol injection. The running carrier fluid was stopped before any study
drugs or test substances were administered. 
Sixty seconds after pretreatment, propofol 2 mg/kg was administered at a rate of 
2.5 mg/s. Patients in groups A and B received 2 mg/kg of premixed lidocaine 1% in 
propofol 1% in a 1:10 ratio at a rate of 990 mL/h by an infusion pump. Patients in
group C received 1% propofol alone at a rate of 900 mL/h.17
The dose of premixed lidocaine in this study was determined based on previous 
research.8,16,17 Because the addition of lidocaine may lead to destabilization of the 
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propofol solution in a dose- and time-dependent manner,21 the mixture was used 
within 30 minutes of preparation.22 An anesthesiologist who was not involved in this
study prepared the drugs before injection at room temperature and programmed the 
infusion pumps in the absence of the blinded observer. The infusion pump was com-
pletely hidden from the blinded observer’s view by an opaque cover. 
The same blinded investigator evaluated the level of pain on injection of propofol 
during the study. Pain scores were recorded using a verbal rating scale: 0 = none 
(negative response to questioning); 1 = mild pain (pain reported in response to ques-
tioning only, without any behavioral sign); 2 = moderate pain (pain reported in re-
sponse to questioning and accompanied by a behavioral sign, or pain reported simul-
taneously without questioning); 3 = severe pain (strong vocal response or response 
accompanied by facial grimacing, arm withdrawal, or tears).8,16,17 If there was no 
spontaneous complaint of pain 10 seconds after the start of the injection, patients were 
repeatedly asked if they felt any pain in the arm until they could not respond. The 
anesthesia was continued with an appropriate technique at the discretion of the at-
tending anesthesiologist. Patients were monitored every 8 hours for 24 hours after
surgery for adverse events at the injection site (eg, pain, edema, wheal, flare response)
by an anesthesiologist blinded to the patient’s group assignment.
Statistical Analyses
Based on identified published studies, we estimated the incidence of pain in patients
receiving placebo to be ~80%.4,15,16 We considered a reduction in the incidence of pain
by half (from 80% to 40%) to be clinically significant. Based on an α error of 0.05 and 
a β error of 0.2, a minimum sample size of 30 patients per group was estimated to be
necessary to detect a significant difference. Statistical analyses were performed with
factorial ANOVA for age, weight, and height, and with the χ2 test for sex and incidence
of pain. Pain intensity scores were compared using the Kruskal-Wallis test. Significance 
was established at P < 0.05. The number needed to treat was calculated. Data were
expressed as mean (SD), number (%), or median, as appropriate. All statistical analyses
were conducted using SPSS software version 12.0 (SPSS Inc., Chicago, Illinois).
RESULTS
A total of 90 patients, 41 men and 49 women aged 19 to 60 years (mean age,
41.7 years; mean weight, 63 kg), were enrolled. Groups were similar with regard to
age, weight, height, gender, and American Society of Anesthesiology Physical Status
Classification (Table I). The overall incidence and severity of pain on propofol injec-
tion in the 3 groups is shown in Table II. The incidence of pain was significantly
lower in patients in group A (16.7%) or B (36.7%) than in group C (83.3%; both, 
P < 0.001). The median pain score was 0 in groups A and B compared with a median 
pain score of 2 in group C (both, P < 0.001). There was no significant difference in 
the incidence of pain between groups A and B. The combination of ketorolac pretreat-
ment and premixed lidocaine (group A) had a significantly lower incidence of moder-
ate (0% vs 33.3%; P < 0.001) and severe pain (0% vs 20%; P = 0.024) compared with
those in the placebo group (group C). However, there were no significant differences
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Table II. Incidence of pain on injection of propofol in Korean patients undergoing elective
plastic surgery (N = 90).
Group A Group B
(Ketorolac + (NS + Lidocaine + Group C
Lidocaine + Propofol) Propofol) (NS + Propofol)
Variable (n = 30) (n = 30) (n = 30)
Patients with pain, no. (%) 5 (16.7)* 11 (36.7)* 25 (83.3)
Pain score, median (range) 0 (0–1)* 0 (0–3)* 2 (0–3)
Grading of pain, no. (%)
None (0) 25 (83.3)* 19 (63.3)* 5 (16.7)
Mild (1) 5 (16.7) 6 (20.0) 9 (30.0)
Moderate (2) 0* 4 (13.3) 10 (33.3)
Severe (3) 0† 1 (3.3) 6 (20.0)
NS = normal saline.
*P < 0.001 versus group C.
†P = 0.024 versus group C.
Table I.  Demographic characteristics of Korean patients undergoing elective plastic
surgery (N = 90).*
Group A Group B
(Ketorolac + (NS + Lidocaine + Group C
Lidocaine + Propofol) Propofol) (NS + Propofol)
Characteristic (n = 30) (n = 30) (n = 30)
Age, mean (SD), y 42.0 (8.5) 42.5 (13.0) 40.5 (14.4)
Sex, no. (%)
 Female 18 (60) 19 (63) 12 (40)
 Male 12 (40) 11 (37) 18 (60)
Weight, mean (SD), kg 63 (11.7) 62 (7.4) 64 (7.4)
Height, mean (SD), cm 167 (8.4) 167 (10.0) 165 (7.9)
ASA physical status,
no. (%)
 I 17 (57) 16 (53) 20 (67)
 II 13 (43) 14 (47) 10 (33)
NS = normal saline; ASA = American Society of Anesthesiologists.
*No significant between-group differences were observed.
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in the incidences of moderate (13.3% vs 33.3%) and severe pain (3.3% vs 20.0%)
between groups B and C. The estimated number needed to treat to reduce pain on 
propofol injection in groups A and B was 1.5 and 2.1, respectively, compared with
group C. There were no adverse events such as pain, edema, wheal, or flare at the in-
jection site within 24 hours after surgery in any of the groups.
DISCUSSION
Although various methods to decrease pain on propofol injection have been investi-
gated, there is no single method that entirely prevents this adverse event. Therefore, 
treatment with a combination of partially effective drugs has been suggested.15,17,20
In this study, combination therapy was more effective in decreasing the incidence of 
moderate or severe pain compared with placebo. There was no significant difference
in the incidence of pain between the groups receiving the premixture of lidocaine in 
propofol with or without ketorolac pretreatment. Both groups had significant reduc-
tion in pain compared with placebo. However, the group pretreated with ketorolac 
(group A) had a greater reduction in the incidence of moderate and severe pain com-
pared with placebo (group C).
Previous research has suggested that increasing the dose of an NSAID may provide
more control of propofol injection pain.23 Therefore, the analgesic effect of increasing 
the dose of ketorolac in combination with lidocaine premixture on propofol injection
pain should be investigated.
These findings should be considered within the context of the limitations of this
study. First, we included the premixed lidocaine group as a positive control and the
placebo group as a negative control. However, the difference in infusion rate of propo-
fol between the groups may have affected the incidence of pain. Second, the sample
size of this study was relatively small, and the exclusion criteria may limit the ability 
to extrapolate the results beyond the selected population.
CONCLUSIONS
In this Korean population, premixed lidocaine in propofol with or without ketorolac pre-
treatment was associated with significantly less pain when compared with placebo. The
combination of ketorolac pretreatment and premixed lidocaine in propofol was more effec-
tive in decreasing the incidence of moderate or severe pain compared with placebo.
ACKNOWLEDGMENTS
No funding was provided in the conduct of this study or the preparation of this paper. 
All authors clearly meet internationally accepted authorship criteria. The authors have 
indicated that they have no conflicts of interest regarding the content of this article.
REFERENCES
1. Smith I, White PF, Nathanson M. Propofol. An update on its clinical use. Anesthesiology. 1994;
81:1005–1043.
2. Helmers JH, Kraaijenhagen RJ, v Leeuwen L, Zuurmond WW. Reduction of pain on injection
caused by propofol. Can J Anaesth. 1990;37:267–268.
357
J. Yeo et al.
3. Hynynen M, Korttila K, Tammisto T. Pain on IV injection of propofol (ICI 35 868) in emul-
sion formulation. Short communication. Acta Anaesthesiol Scand. 1985;29:651–652.
4. Pang WW, Mok MS, Huang S, Hwang MH. The analgesic effect of fentanyl, morphine,
meperidine, and lidocaine in the peripheral veins: A comparative study. Anesth Analg. 1998;
86:382–386.
5. Picard P, Tramèr MR. Prevention of pain on injection with propofol: A quantitative systematic 
review. Anesth Analg. 2000;90:963–969.
6. Yamakage M, Iwasaki S, Satoh J, Namiki A. Changes in concentrations of free propofol by 
modification of the solution. Anesth Analg. 2005;101:385–388.
7. Scott RP, Saunders DA, Norman J. Propofol: Clinical strategies for preventing the pain of 
injection. Anaesthesia. 1988;43:492–494.
8. Tan LH, Hwang NC. The effect of mixing lidocaine with propofol on the dose of propofol
required for induction of anesthesia. Anesth Analg. 2003;97:461–464.
9. Arndt JO, Klement W. Pain evoked by polymodal stimulation of hand veins in humans. 
J Physiol. 1991;440:467–478.
10. Nakane M, Iwama H. A potential mechanism of propofol-induced pain on injection based on
studies using nafamostat mesilate. Br J Anaesth. 1999;83:397–404.
11. Briggs LP, Clarke RS, Dundee JW, et al. Use of di-isopropyl phenol as main agent for short 
procedures. Br J Anaesth. 1981;53:1197–1202.
12. Doenicke AW, Roizen MF, Rau J, et al. Reducing pain during propofol injection: The role of 
the solvent. Anesth Analg. 1996;82:472–474.
13. Iwama H, Nakane M, Ohmori S, et al. Nafamostat mesilate, a kallikrein inhibitor, prevents
pain on injection with propofol. Br J Anaesth. 1998;81:963–964.
14. Yull DN, Barkshire KF, Dexter T. Pretreatment with ketorolac and venous occlusion to reduce 
pain on injection of propofol. Anaesthesia. 2000;55:284–287.
15. Fujii Y, Nakayama M. A lidocaine/metoclopramide combination decreases pain on injection of 
propofol. Can J Anaesth. 2005;52:474–477.
16. King SY, Davis FM, Wells JE, et al. Lidocaine for the prevention of pain due to injection of 
propofol. Anesth Analg. 1992;74:246–249.
17. Kwak K, Kim J, Park S, et al. Reduction of pain on injection of propofol: Combination of 
pretreatment of remifentanil and premixture of lidocaine with propofol. Eur J Anaesthesiol.
2007;24:746–750.
18. Rømsing J, Ostergaard D, Walther-Larsen S, Valentin N. Analgesic efficacy and safety of pre-
operative versus postoperative ketorolac in paediatric tonsillectomy. Acta Anaesthesiol Scand.
1998;42;770–775.
19. Huang YW, Buerkle H, Lee TH, et al. Effect of pretreatment with ketorolac on propofol injec-
tion pain. Acta Anaesthesiol Scand. 2002;46:1021–1024.
20. Aouad MT, Siddik-Sayyid SM, Al-Alami AA, Baraka AS. Multimodal analgesia to prevent 
propofol-induced pain: Pretreatment with remifentanil and lidocaine versus remifentanil or
lidocaine alone. Anesth Analg. 2007;104:1540–1544.
21. Lilley EM, Isert PR, Carasso ML, Kennedy RA. The effect of the addition of lignocaine on 
propofol emulsion stability. Anaesthesia. 1996;51:815–818.
22. Masaki Y, Tanaka M, Nishikawa T. Changes in propofol concentration in a propofol-lidocaine
9:1 volume mixture. Anesth Analg. 2000;90:989–992.
Current Therapeutic Research
358
23. Fujii Y, Itakura M. Pretreatment with flurbiprofen axetil, flurbiprofen axetil preceded by
venous occlusion, and a mixture of flurbiprofen axetil and propofol in reducing pain on
injection of propofol in adult Japanese surgical patients: A prospective, randomized, double-
blind, placebo-controlled study. Clin Ther. 2009;31:721–727.
Address correspondence to: Younghoon Jeon, MD, Department of 
Anesthesiology and Pain Medicine, School of Medicine, Kyungpook National
University, 200 Donduk-ro, Jung-gu, Daegu, 700-721, Republic of Korea. E-mail:
jeon68@knu.ac.kr
